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Introduction
The OPTIMAprelim pilot trial in early breast cancer
aims to select multi-parameter tests for inclusion in a
phase III trial evaluating their use for patient selection
for chemotherapy. Patients are randomised between uni-
versal chemotherapy or test-directed chemotherapy.
A key criterion for inclusion of a test as a comparator will
be the expected value of further research into its clinical
and cost-effectiveness.
Methods
In order to conduct a Value-of-Information (VoI) Analy-
sis a probabilistic decision model was developed to evalu-
ate the cost-effectiveness of a personalised treatment
strategy based on each of the candidate tests from a UK
NHS perspective. Concordance/discordance with Onco-
type DX, the gold standard test, was used to model
expected sensitivity and specificity of alternative tests.
Results
Decision analytic models of test guided cancer therapy
require the explicit characterisation of test performance
for different test definitions and survival conditional
upon test result. In this example, modelling the required
outcome data, dependent on the modelled test result,
was feasible although likely represents an underestimate
of the true uncertainty. It was possible to describe rela-
tive value of research on the test characteristics versus
research on chemotherapy effectiveness across test-
defined patient sub-groups. Modelling solutions which
consider alternative test cut-points and time-dependent
outcomes are presented.
Conclusion
Characterising the uncertainty and value of information
associated with test performance parameters and the
expected outcomes conditional upon test results is feasi-
ble on the basis of test concordance data, even with lim-
ited current long term outcomes data.
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